A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the concentration of canagliflozin in blood and
urine samples after the administration of canagliflozin to study participants with mild or
moderate hepatic (liver) impairment compared with study participants with normal hepatic
function.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.